DBV Technologies | DBVT - Assets

Stock Price
21.94
Daily Change
0.71 3.32%
Monthly
-4.09%
Yearly
435.00%
Q1 Forecast
20.91

DBV Technologies reported $110.49M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 659.81M 10.31M Sep/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
United Therapeutics USD 7.35B 556.9M Sep/2025